You are here

A Therapeutic for Radiation Induced Lung Injury

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI110004-01
Agency Tracking Number: R43AI110004
Amount: $299,948.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA12-044
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
51 Charles Lindbergh Blvd
Uniondale, NY 11553-3658
United States
DUNS: 53129065
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 LATHA PAKA
 (516) 562-1278
 spaka@angion.com
Business Contact
 ITXHAK GOLDGERG
Phone: (516) 326-1200
Email: igoldberg@angion.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Nuclear accidents and terrorism present a serious threat for causing mass-casualty scenarios. In radiation events, many people receive non-uniform whole-body or partial-body irradiation. The risk of exposure to ionizingradiation due to terrorist activities could result in acute injury as well as long-term adverse health effects in thousands of people. The lung is one of the more radiosensitive organs and inhaling large quantities of radionuclides produces a spectrum ofsevere functional and morphological changes, ranging from radiation pneumonitis and pulmonary fibrosis. Although efforts to find suitable radiation countermeasures were initiated more than 50 years ago, no safe and effective radiation countermeasure has been approved by the Food and Drug Administration (FDA). Thus, there is a pressing need for radiation countermeasures. Hepatocyte growth factor (HGF) is a paracrine growth factor produced by cells of mesenchymal origin; Activation of the HGF pathway is

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government